EpCAM-autoantibody levels in the course of disease of ovarian cancer patients.
EpCAM is a tumor-associated antigen, which is frequently expressed in ovarian cancer. Recently, autoantibodies against EpCAM have been identified in patients with ovarian cancer. It is not clear whether these autoantibodies are of prognostic importance. We evaluated whether EpCAM-autoantibodies have an impact on the clinical course of patients with ovarian cancer. EpCAM-autoantibodies were determined in sera of 28 healthy voluntary age-matched women and 84 patients with primary epithelial ovarian cancer before and after platinum-based chemotherapy using a recombinant EpCAM-protein for antibody detection by ELISA technique. The median follow-up time was 18 months. Samples exceeding the mean antibody titer of healthy controls plus 2 standard deviations were considered positive. The antibody titer of healthy controls was 0.061 ± 0.015. Using a cut-off value of 0.091, we found 3/84 (4%) patients before and 12/61 (20%) patients with ovarian cancer to be positive for EpCAM-autoantibodies after first-line treatment. Using the paired T-Test, we noted a significant post-therapeutic increase of AABs (P < 0.0001). Notably, AAB-levels after first-line therapy were found to be correlated with the tumor resection status in primary surgery. Analysis of progression-free survival, FIGO stage, grading, age and sensitivity to platinum-based chemotherapy did not reveal significant associations with EpCAM-AAB titers. We observed an increase in AAB-levels during the first-line treatment of patients with ovarian cancer. EpCAM-AAB-levels after first-line treatment appear to correlate with macroscopic tumor residuals after initial surgery.
Heubner
Martin
M
Clinic of Obstetrics and Gynaecology, Medical Faculty, University of Duisburg-Essen, Essen, Germany. Martin.heubner@uk-essen.de
Errico
Dino
D
Kasimir-Bauer
Sabine
S
Herlyn
Dorothee
D
Kimmig
Rainer
R
Wimberger
Pauline
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000097:blood / Q000276:immunology*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D001324:Autoantigens / Q000276:immunology; D015815:Cell Adhesion Molecules / Q000097:blood / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D000071858:Epithelial Cell Adhesion Molecule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D011379:Prognosis; D055815:Young Adult
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D001323:Autoantibodies; D001324:Autoantigens; D015815:Cell Adhesion Molecules; C499379:EPCAM protein, human; D000071858:Epithelial Cell Adhesion Molecule
Cancer Res. 1987 Jun 1;47(11):2883-91
3552208
Oncogene. 2004 Jul 29;23(34):5748-58
15195135
Cancer Immunol Immunother. 1999 Feb;47(6):315-20
10203061
Int J Gynaecol Obstet. 2009 Apr;105(1):3-4
19322933
Cancer. 2003 May 15;97(10 Suppl):2676-85
12733132
Otolaryngol Head Neck Surg. 2009 Mar;140(3):375-80
19248946
Ann Oncol. 2006 Oct;17(10):1568-77
17005631
J Cell Biol. 1994 Apr;125(2):437-46
8163559
J Cell Biol. 1997 Dec 1;139(5):1337-48
9382878
J Immunol Methods. 2002 Dec 15;270(2):227-33
12379327
Int J Urol. 2004 Dec;11(12):1070-7
15663677
Clin Cancer Res. 2003 Oct 15;9(13):4782-91
14581349
Am J Pathol. 2003 Dec;163(6):2139-48
14633587
Breast Cancer Res Treat. 1985;6(1):57-65
3902126
Clin Cancer Res. 2007 Jul 1;13(13):3899-905
17606723
Clin Cancer Res. 2008 Jun 15;14(12):3896-905
18559611
Nat Cell Biol. 2009 Feb;11(2):162-71
19136966
Odontology. 2008 Jul;96(1):32-7
18661202
Int J Gynecol Pathol. 2000 Jan;19(1):7-15
10638449
Cancer Res. 1992 Feb 15;52(4):815-21
1737342
Immunol Rev. 2002 Oct;188:122-35
12445286